<DOC>
	<DOCNO>NCT02580019</DOCNO>
	<brief_summary>The study aim estimate safety efficacy intravenous injection human umbilical cord mesenchymal stem cell ( hUC-MSC ) patient suffer ischemic stroke recent 3 month .</brief_summary>
	<brief_title>Umbilical Cord Derived Mesenchymal Stem Cells Treatment Ischemic Stroke</brief_title>
	<detailed_description>Given attention pay recent time , China elsewhere , stroke , lead cause acquire adult disability negative effect patient ' quality life.Therefore , It 's little wonder 's much focus day treatment stroke . For patient suffered ischemic stroke 3 month , indeed , opportunity get symptomatic improvement receive conventional stroke treatment include rehabilitation . At time , treatment ineffective case . Alternatively , phenomenon increase brain plasticity stroke provoke essential therapy . Human umbilical cord mesenchymal stem cell treatment enhance functional improvement cerebral ischemia , likewise , treament rodent model prove effective . Human umbilical cord mesenchymal stem cell therapy perform role take place destroyed cerebral tissue stem cell graft . The totality evidence trial run umbilical cord mesenchymal stem cell transplant patient suffer ischemic stroke support safety approach . In term efficacy , positive result report majority trial . Our research project involve development cell therapy phase IIa clinical trial safety efficacy patient ( randomise , control , open , 2 parallel group ) .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<criteria>Confirmed diagnosis intracerebral ischemic stroke three month Magnetic Resonance Imaging ( MRI ) Patients receive proper treatment within two week onset stroke symptom . Age 18 70 year old men woman Patients persistent neurological deficit . Obtaining informed consent sign ( inform purpose , procedure , venture study , patient guardian legal representative must sign informed consent document engagement participation . Patients basic situation allowable involved program . Patients serious extensive stroke , unwilling risk . Patients serious persistent neurological deficit ( NIHSS &gt; 24 ) . Medical history neurological pathology deficit consequence ( Rankin &lt; 3 stroke ) . Patients serious psychological disease . Patients myocardial infarction recent 3 month . Patients recur thromboembolic disease recentin recent 3 month . Patients organ transplantation . Patients infection history include Human Immunodeficiency Virus ( HIV ) , Human Tcell Leukemia Virus ( HTLV ) , Hepatitis B Virus ( HBV ) , Hepatitis C Virus ( HCV ) , ect . Patients receive current immunosuppressive/immunomodulating treatment . Patients basic situation unallowable involved program . Patients refuse participate . Patients inability unwillingness individual legal guardian/representative give write informed consent . Patients pregnant feeding woman . Patients Participating another therapeutic clinical trial period exclusion therapeutic clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Cellular therapy</keyword>
	<keyword>Stroke</keyword>
	<keyword>Neuronal Plasticity</keyword>
	<keyword>Recovery</keyword>
	<keyword>umbilical cord mesenchymal stem cell</keyword>
	<keyword>Transplantation</keyword>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Ischemia</keyword>
	<keyword>Brain Infarction</keyword>
	<keyword>Brain Ischemia</keyword>
	<keyword>Cerebrovascular Disorders</keyword>
</DOC>